Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for RYTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -105.35M
March 31, 2026 -119.51M
December 31, 2025 -115.68M
September 30, 2025 -109.13M
June 30, 2025 -107.72M
March 31, 2025 -113.49M
December 31, 2024 -113.88M
September 30, 2024 -124.42M
June 30, 2024 -128.45M
March 31, 2024 -140.47M
December 31, 2023 -136.16M
September 30, 2023 -140.77M
June 30, 2023 -158.51M
March 31, 2023 -156.23M
December 31, 2022 -173.43M
September 30, 2022 -179.90M
June 30, 2022 -173.07M
March 31, 2022 -166.10M
December 31, 2021 -146.00M
September 30, 2021 -134.65M
Date Value
June 30, 2021 -121.52M
March 31, 2021 -119.41M
December 31, 2020 -121.98M
September 30, 2020 -125.08M
June 30, 2020 -131.65M
March 31, 2020 -127.47M
December 31, 2019 -122.75M
September 30, 2019 -111.51M
June 30, 2019 -94.85M
March 31, 2019 -81.78M
December 31, 2018 -62.06M
September 30, 2018 -48.96M
June 30, 2018 -40.43M
March 31, 2018 -34.10M
December 31, 2017 -29.46M
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016 -20.48M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 160.32M
Alnylam Pharmaceuticals, Inc. 885.89M
BioMarin Pharmaceutical, Inc. 857.09M
Cytokinetics, Inc. -555.45M
Exelixis, Inc. 1.183B